This website is intended for healthcare professionals only

Trending Topic

4 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Personalized and predictive dermatology recognizes that each patient is unique and aims to comprehensively address all aspects of an individual’s skin health. This approach tailors skin care treatments based on a combination of factors, including genetic and epigenetic profiles, skin type, microbiome composition and the exposome (an individual’s lifetime exposures).1 Scientists are exploring how ecological […]

Could rezpegaldesleukin offer long-term remission in atopic dermatitis?

Thomas Bieber
4 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
EADV 2026
Published Online: Oct 16th 2026

Thomas Bieber discusses the latest REZOLVE-AD findings and the potential for REZPEG to offer long-term remission and, potentially, disease modification in AD. 


zenas yiu

“…the potential of REZPEG lies in the possibility of achieving long-term remission, perhaps even after treatment has stopped. ”

Rezpegaldesleukin (REZPEG) is an investigational interleukin-2 (IL-2) receptor pathway agonist designed to increase the number and enhance the function of regulatory T cells (Tregs). It represents a novel therapeutic approach being investigated for atopic dermatitis (AD). It is hoped that by targeting a different immune pathway, REZPEG could offer sustained disease control with less frequent maintenance dosing.

New 52-week data from the phase 2b REZOLVE-AD study (NCT06136741), including results from its 36-week blinded maintenance period, were presented at the EADV 2026 Congress. The findings showed that monthly and quarterly maintenance dosing produced durable responses, with further improvements in the signs and symptoms of AD through Week 52, including complete disease clearance in some patients.

Following his presentation, we spoke with Prof. Thomas Bieber (Ludwig-Maximilians University Hospital, Munich, Germany) about the study’s findings and their potential implications for clinical practice and people living with AD.


Q. What has REZOLVE-AD shown about the efficacy and durability of response of REZPEG in AD?

The phase 2b REZOLVE-AD trial of REZPEG in AD has demonstrated clear efficacy compared with placebo. However, when discussing efficacy, people typically compare this drug with dupilumab, which is considered the gold standard. In my opinion, a common mistake is to compare the Week 16 results for dupilumab with those of every other drug in development, as these drugs have different mechanisms of action and different timelines for clinical response.

For example, treatments such as REZPEG have the potential to show efficacy at Week 16, but their greatest value may lie in what we see at Week 52 and beyond. This relates to its mechanism of action: the Treg population needs time to expand, and those cells then need time to influence the ongoing inflammation.

I would say that the potential of REZPEG lies in the possibility of achieving long-term remission, perhaps even after treatment has stopped. It belongs to a new generation of therapies with which we hope that, after treating patients for 1 year or 1.5 years, we might be able to stop treatment completely if their disease is fully controlled.

If achieved, this could transform the lives of patients and their families.


Q. What has the study demonstrated in terms of safety and tolerability of REZPEG?

Safety is always an important consideration in clinical development. So far, we have phase 2b results from a few hundred patients, rather than several thousand.

The safety profile has been encouraging. Apart from some injection site reactions, we have not seen any major safety signals or other notable findings compared with placebo. These findings give us confidence, but we need to retain that caveat about the number of patients treated. Larger studies involving several thousand patients will be needed to characterize the safety profile more fully.

In terms of tolerability, we know from oncology trials that injecting cytokines such as IL-2 can cause transient local reactions. Encouragingly, we have seen these reactions decrease over time in most patients in this trial. I believe only one patient stopped treatment because of an injection site reaction. This suggests that, for most patients, these reactions were manageable and did not lead them to discontinue treatment.


Q. What are the next steps in exploring its potential in these populations?

The next step will be to investigate what happens if treatment is stopped after 1 year. Could patients achieve the ultimate goal of long-term remission without continued treatment?

This is the potential for disease modification that we hope to explore: whether enhancing the Treg response could suppress the ongoing chronic inflammation and allow disease control to persist after treatment has stopped. This approach may also have potential in other inflammatory diseases.

If we could achieve that goal, it could transform patients’ lives and, in my view, represent a major advance in managing AD. However, we must remain cautious and wait for further evidence to establish whether this drug can deliver that outcome.

In addition, we should not expect a single treatment to work for everyone. AD is complex, both in its clinical presentation and its underlying immunology, so not all patients would be expected to achieve long-term remission. However, if around half, or perhaps more, of those treated could achieve that goal, it would be a remarkable outcome.


Related abstract: Bieber T, Rosmarin D, Warren RB, et al. Rezpegaldesleukin provides durable and deepening improvements in the signs and symptoms of atopic dermatitis with monthly and quarterly dosing: Results from the phase 2b REZOLVE-AD maintenance part of study. Presented at: EADV Congress 2026, Vienna, Austria, 1 October, 2026. Abstr#1732.

 

Cite: Real-world outcomes of bimekizumab in hidradenitis suppurativa. touchDERMATOLOGY. 16 October, 2026.

Disclosures: No funding was received for the publication of this content. We thank Prof. Bieber for sharing his expert perspectives. Prof. Bieber discloses current or previous roles as a speaker and/or consultant for AbbVie, Aclaris, Almirall, AnaptysBio, Apogee, Arcutis, Artax, Attovia, Bambusa, Belenos, Biocryst, Biogeneration, BioVerSys, Bluefine, Böhringer-Ingelheim, Bristol-Myers Squibb, BYOME Labs, Cantargia, CellDex, Choate, Claris Venture, Corvus, DirigentBio, Domain Therapeutics, Eggle, EngImmune, Ennovate, Evommune, Forbion, Formycon, Galderma, Gilead, GSK, ImagGeneBio, Janssen, Kyowa/Kirin, Kymera, LEO, Lilly, Mabylon, MSD, Micreos, Nektar, Nextech, Novartis, Pfizer, Pierre Fabre, Protagonist Tx, Samsung Bioepis, Sanofi/Regeneron, Scienta Lab, Serono, SwitchKine, TIRmed, Triton, Triveni, UCB, Union Therapeutics, UPStream Bio, WinWard, YUHAN, and Zurabio. He is the founder and chairman of the board of the nonprofit biotechnology company Davos Biosciences AG, within the international Kühne-Foundation. He is also the founder and senior medical advisor of Bieber Dermatology Consulting.

Editor: Gina Furnival, Head of Content

touchDERMATOLOGY coverage of EADV 2026: This content has been developed independently by Touch Medical Media for touchDERMATOLOGY. touchDERMATOLOGY was an official media partner of the EADV Congress 2026. touchDERMATOLOGY is not affiliated with the EADV. Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.

 

 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Open Nav
touchConference Hub
Section 2 of 3 Part 6 of 9

touchDERMATOLOGY coverage of EADV Congress 2026

Prev Part
Next Part
touchConference Hub

touchDERMATOLOGY coverage of EADV Congress 2026

Late-breaking data

Further APEX data supports zumilokibart's potential as a less frequent dosing biologic option for atopic dermatitis; Melinda Gooderham
Further APEX data supports zumilokibart's potential as a less frequent dosing biologic option for atopic dermatitis; Melinda Gooderham

Further APEX data supports zumilokibart’s potential as a less frequent dosing option for atopic dermatitis

Part B of the phase 2 APEX trial evaluated three zumilokibart dosing regimens in adults with moderate-to-severe atopic dermatitis. All three met the primary endpoint at Week 16, with findings supporting mid dose selection for phase 3. Dr Melinda Gooderham discusses the efficacy and safety results from both Part A and Part B and what they could mean for clinical practice and those living with AD.
Abdakibart in hidradenitis suppurativa: What we learned from LOTUS; Martina Porter
Abdakibart in hidradenitis suppurativa: What we learned from LOTUS; Martina Porter

Abdakibart in hidradenitis suppurativa: What we learned from LOTUS

Could abdakibart offer a new treatment option for hidradenitis suppurativa? Dr Martina L. Porter discusses encouraging findings from the phase 2 LOTUS trial, including improvements in disease severity and draining tunnels, alongside a reassuring safety profile over 16 weeks, and considers what these results could mean for clinical practice.
Safety of dupilumab in pregnancy explored in final registry results
Safety of dupilumab in pregnancy explored in final registry results

Safety of dupilumab in pregnancy explored in final registry results

For women taking dupilumab to manage atopic dermatitis or asthma, limited pregnancy safety data can make treatment decisions challenging. Dr Christina Chambers discusses reassuring findings from a registry study of 539 pregnancies and how they could help clinicians counsel women who are pregnant or planning a family.

JAKPPPOT investigates the feasibility of a definitive JAKi trial in palmoplantar pustulosis

Encouraging findings from JAKPPPOT support the feasibility of a definitive randomized controlled trial of Janus kinase inhibitors in palmoplantar pustulosis and provide an exploratory estimate of treatment effect. We spoke with Dr David Gleeson about the results presented at EADV 2026 and their implications for future research.
0 mins

Topical RLS-1496 reduces actinic keratosis lesion counts

RLS-1496 1% cream is an investigational senotherapeutic treatment that inhibits GPX4. It aims to target senescent cells, potentially offering a new approach to treating actinic keratosis (AK). Encouraging findings from a phase 1b/2a, multicenter, open-label study were presented at EADV 2026. We spoke with Dr Mary Spellman, who presented the findings, about the results and their implications for the treatment’s future development.
Show All...
Currently viewing

Expert insights

Sonelokimab shows potential in treating palmoplantar pustulosis in LEDA trial
Sonelokimab shows potential in treating palmoplantar pustulosis in LEDA trial

Sonelokimab shows potential in treating palmoplantar pustulosis in LEDA trial

Sonelokimab showed encouraging results in the phase 2 LEDA trial in adults with palmoplantar pustulosis. Dr Nina Magnolo discusses the findings, including a mean 64% reduction in disease severity at Week 16, and their potential implications for patients.
Mario Valenti, bimekizumab in hidradenitis suppurativa
Mario Valenti, bimekizumab in hidradenitis suppurativa

Real-world outcomes of bimekizumab in hidradenitis suppurativa

How does bimekizumab perform in everyday clinical practice? An Italian multicenter study reported improvements in disease activity, pain, and quality of life in people with hidradenitis suppurativa, with no unexpected safety signals. Dr Mario Valenti shares the findings and his perspective with touchDERMATOLOGY.
Prof. Dédée Murrell; The Women’s Dermatologic Society
Prof. Dédée Murrell; The Women’s Dermatologic Society

Drug repurposing to advance treatment for rare genetic skin diseases

Drug repurposing could offer new treatment opportunities for rare genetic skin diseases. Prof. Dédée Murrell discusses the rationale for exploring existing medicines, progress in epidermolysis bullosa, and how a new trial aims to match treatments to patients’ inflammatory profiles rather than their genetic subtype.
Maria-Angeliki Gkini
Maria-Angeliki Gkini

EADV 2026: Psoriasis highlights and implications for clinical practice

On Day 2 of the EADV 2026 congress, we were delighted to speak with touchDERMATOLOGY Editorial Board member, Dr Maria Angeliki Gkini who shared her highlights from key psoriasis sessions and discussed what these developments could mean for clinical practice.
Prof. Dédée Murrell; The Women’s Dermatologic Society
Prof. Dédée Murrell; The Women’s Dermatologic Society

The Women’s Dermatologic Society at EADV 2026

What did the Women’s Dermatologic Society bring to EADV 2026? Explore session highlights spanning blistering diseases, skin cancer, scarring alopecias, and more. Prof. Dedee Murrell introduces the society’s focus on mentorship, explains why the session is worth watching, and shares why dermatologists should consider joining.

Could rezpegaldesleukin offer long-term remission in atopic dermatitis?

New 52-week REZOLVE-AD data showed durable responses with monthly and quarterly rezpegaldesleukin (REZPEG) maintenance dosing in atopic dermatitis. Prof. Thomas Bieber discusses the findings and the potential for long-term remission and disease modification, highlighting the further evidence needed to explore these goals.
Dr Melinda Gooderham reflects on her EADV 2026 highlights, including updates in JAKi, zasocitinib vs. deucravacitinib, and the ICONIC-TOTAL findings on icotrokinra in psoriasis.
Dr Melinda Gooderham reflects on her EADV 2026 highlights, including updates in JAKi, zasocitinib vs. deucravacitinib, and the ICONIC-TOTAL findings on icotrokinra in psoriasis.

EADV 2026 highlights with Dr Melinda Gooderham

What were the key dermatology updates at EADV 2026? Dr Melinda Gooderham shares her highlights, exploring the Janus kinase (JAK) inhibitors session, new data comparing zasocitinib with deucravacitinib, and 2-year findings from ICONIC-TOTAL evaluating icotrokinra.
Ashraf Badawi
Ashraf Badawi

Key updates in the field of laser and energy-based devices

From pruritus and burn scars to cutaneous neurofibromas, Prof. Ashraf Badawi explores some of the new directions for lasers and energy-based devices discussed at this years EADV congress.

Study links glucagon-like peptide-1 receptor agonist use with nail disorders

Could glucagon-like peptide-1 receptor agonists affect nail health? A multinational study presented at EADV 2026 found nail disorders were reported more frequently among users, with nearly sevenfold higher odds of nail detachment. Prof. Bianca Maria Piraccini discusses the findings and why further clinical assessment is needed.
Show All...

News

3 mins

touchDERMATOLOGY announces new media partnership with the EADV Congress

Through our new collaboration, we will work together to increase the visibility of important developments in dermatology, from the latest clinical research and scientific advances to key society news and updates. As part of the partnership, touchDERMATOLOGY will also bring our community independent coverage directly from the EADV Congress, including the latest data, expert perspectives, key clinical takeaways and onsite interviews with leading specialists.
3 mins

Your quick guide to keynote and plenary sessions at EADV 2026

With EADV Congress 2026 just around the corner, there is plenty to look forward to in Vienna from 30 September to 3 October. If you are joining this year, whether onsite or online, the keynote and plenary sessions are well worth making time for in your congress schedule.

Day 1: Late breakers, JAK inhibitors and keynote lecture open EADV 2026

The EADV Congress opens in Vienna on Wednesday, 30 September. Day 1 highlights include a midday plenary, two late-breaking sessions, a focus on JAK inhibitors, and a closing keynote on the COVID-19 pandemic and the infodemic.
Close Popup